齐鲁制药荣获2025“责任耀齐鲁”年度责任企业

Group 1 - The "2025 Responsibility Shine Qilu" annual event recognized Qilu Pharmaceutical as a "Responsible Enterprise" for its outstanding performance in drug research and development, public health support, and industry responsibility [1] - The event was attended by leaders from the Shandong Provincial Health Commission, Shandong Digital Culture Group, and representatives from nearly a hundred medical institutions, highlighting the importance of recognizing contributions to the health sector in Shandong [1] - The awards were based on public recommendations, sentiment analysis, big data evaluation, and reader feedback, aiming to set benchmarks for industry responsibility [1] Group 2 - Qilu Pharmaceutical focuses on major diseases such as tumors, infections, and autoimmune diseases, increasing R&D investment and establishing a global innovation platform to ensure high-quality drug supply [2] - The company has implemented a comprehensive quality control system and adheres to international standards to ensure the safety and reliability of its products [2] - Qilu Pharmaceutical actively engages in social responsibility through initiatives like "Healthy China, Qilu Together," providing free health screenings and educational outreach in underserved areas [2] Group 3 - In 2025, Qilu Pharmaceutical achieved significant breakthroughs, including multiple innovative drugs entering critical clinical trial phases and establishing a leading smart pharmaceutical production base [3] - The company has enhanced production efficiency and quality control through digital and intelligent transformations, ensuring stable drug supply [3] - Qilu Pharmaceutical aims to continue its commitment to pharmaceutical innovation and public health services, responding to national health initiatives and driving high-quality development in the Chinese pharmaceutical industry [3]